Genenta Science S.p.A. Enters into Letter of Intent with AGC Biologics S.p.A - Marketscreener.com
GNTA Stock | USD 5.20 0.18 3.35% |
About 64% of Genenta Science's investor base is looking to short. The analysis of the overall investor sentiment regarding Genenta Science SpA suggests that many traders are alarmed. The current market sentiment, together with Genenta Science's historical and current headlines, can help investors time the market. In addition, many technical investors use Genenta Science SpA stock news signals to limit their universe of possible portfolio assets.
Genenta |
Genenta Science S.p.A. Enters into Letter of Intent with AGC Biologics S.p.A Marketscreener.com
Read at news.google.com
Genenta Science Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Genenta Science can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Genenta Science Fundamental Analysis
We analyze Genenta Science's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genenta Science using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genenta Science based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Genenta Science is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Genenta Science SpA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genenta Science stock to make a market-neutral strategy. Peer analysis of Genenta Science could also be used in its relative valuation, which is a method of valuing Genenta Science by comparing valuation metrics with similar companies.
Peers
Genenta Science Related Equities
ANTX | AN2 Therapeutics | 21.90 | ||||
OPT | Opthea | 10.81 | ||||
CSBR | Champions Oncology | 4.87 | ||||
MNOV | MediciNova | 2.99 | ||||
ADAG | Adagene | 1.30 | ||||
PMVP | Pmv Pharmaceuticals | 1.25 | ||||
RZLT | Rezolute | 1.00 | ||||
ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
MOLN | Molecular Partners | 0.17 | ||||
AVTE | Aerovate Therapeutics | 0.38 | ||||
PEPG | PepGen | 0.98 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
PHVS | Pharvaris | 2.06 | ||||
JANX | Janux Therapeutics | 2.54 | ||||
MLYS | Mineralys Therapeutics, | 2.59 |
Complementary Tools for Genenta Stock analysis
When running Genenta Science's price analysis, check to measure Genenta Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genenta Science is operating at the current time. Most of Genenta Science's value examination focuses on studying past and present price action to predict the probability of Genenta Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genenta Science's price. Additionally, you may evaluate how the addition of Genenta Science to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |